Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic
This article was originally published in PharmAsia News
MUMBAI - Continuing with its strategy to aggressively pursue in-licensing of novel R&D from Asia, French drug maker Sanofi signed a deal with India's Glenmark Pharmaceuticals Ltd. for the development and commercialization of GBR 500 - a novel monoclonal antibody for the treatment of Crohn's disease and other inflammatory conditions. The present market size for Crohn's disease is $2-3 billion, executives at Glenmark said, terming the first ever deal for a biological candidate from India as "landmark.
You may also be interested in...
Glenmark’s Pain Drug Fails To Meet Primary Endpoint, Path Of Another Altered By Sanofi
Indian drug maker Glenmark disclosed that Sanofi shelved research on one of its compounds and altered the indication of another biologic for multiple sclerosis treatment.
With Its Third Biologic, India’s Glenmark Claims Success With Anti-OX40 MAb
Glenmark’s Swiss research center is bulking up its pipeline as its third discovery advances to the clinic.
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.